Engineered nucleases and their uses for nucleic acid assembly
Aspects of the invention provide engineered endonucleases that are characterized by both a long recognition sequence and specific cleavage outside of the recognition site. Engineered endonucleases of the invention are useful for manipulating long pieces of DNA.
1. An engineered chimeric endonuclease comprising:
the nucleic acid binding domain of a nuclease deficient I-SceI linked to the nucleic acid cleavage domain of FokI,
wherein the nucleic acid binding domain of I-SceI endonuclease comprises an amino acid substitution at position 44 and 145, wherein the wild type residue aspartic acid (D) at position 44 is replaced with asparagine (N) or alanine (A) and wherein the wild type residue aspartic acid (D) at position 145 is replaced with alanine (A),
wherein the engineered chimeric endonuclease binds a recognition sequence motif recognized by I-SceI, and
wherein the engineered chimeric endonuclease cleaves at a unique cleavage position outside of the I-SceI recognition sequence motif.
2. The engineered chimeric endonuclease of claim 1 , wherein the nucleic acid binding domain is a DNA binding domain.
3. The engineered chimeric endonuclease of claim 1 , wherein the nucleic acid binding domain binds to a double-stranded recognition sequence motif.
4. The engineered chimeric endonuclease of claim 1 , wherein the nucleic acid binding domain binds with nanomolar affinity to a target nucleic acid comprising the recognition sequence motif.
5. The engineered chimeric endonuclease of claim 1 , wherein the nucleic acid binding domain is an inactive mutant catalytic domain of I-SceI.
6. The engineered chimeric endonuclease of claim 5 , wherein the amino acid substitutions in the nucleic acid binding domain inactivate the catalytic endonuclease activity of I-SceI.
7. The engineered chimeric endonuclease of claim 1 , wherein the cleavage domain comprises two identical FokI catalytic domains, two different FokI catalytic domains or a FokI catalytic domain and a catalytic domain from a different Type IIS endonuclease.
8. The engineered chimeric endonuclease of claim 7 , wherein the cleavage domain comprises a catalytic domain from a BstF5 I, BtsC I, BsrD I, Bts I, Alw I, Bcc I, BsmA I, Ear I, Mly I, Ple I, Bmr I, Bsa I, BsmB I, Fau I, Mnl I, Sap I, Bbs I, BciV I, Hph I, Mbo II, BfuA I, BspCN I, BspM I, SfaN I, Hga I, BseR I, Bbv I, Eci I, BceA I, BsmF I, BtgZ I, BpuE I, Bsg I, Mme I, BseG I, Bse3D I, BseM I, AclW I, Alw26 I, Bst6 I, BstMA I, Eam1104 I, Ksp632 I, Pps I, Sch I, Bfi I, Bso31 I, BspTN I, Eco31 I, Esp3 I, Smu I, Bfu I, Bpi I, BpuA I, BstV2 I, AsuHP I, Acc36 I, Lwe I, Aar I, BseM II, TspDT I, TspGW I, BseX I, BstV1 I, Eco57 I, Eco57M I, Gsu I, or a Bcg I Type IIS endonuclease.
9. The engineered chimeric endonuclease of claim 1 , wherein the cleavage domain comprises at least one catalytic domain of a Fok I restriction endonuclease.
10. The engineered chimeric endonuclease of claim 9 , wherein the cleavage domain comprises the at least one catalytic domain of a FokI restriction endonuclease associated with at least one portion of a DNA recognition subdomain of the FokI restriction endonuclease.
11. The engineered chimeric endonuclease of claim 1 , wherein the nucleic acid binding domain and the nucleic acid cleavage domain are covalently linked without an intervening synthetic peptide linker.
12. The engineered chimeric endonuclease of claim 1 , wherein the nucleic acid binding domain and the nucleic acid cleavage domain are linked via an intervening synthetic peptide linker.